Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma is used to treat hypertension by targeting multiple pathways that regulate blood pressure.

• Essential hypertension: lowers systolic and diastolic blood pressure.
• Secondary hypertension: provides additive control when monotherapy is insufficient.
• Hypertensive patients with fluid retention: combines diuretic effect to reduce volume overload.

• The drug combines three agents: olmesartan medoxomil selectively blocks angiotensin II type‑1 receptors, preventing vasoconstriction and aldosterone release; amlodipine inhibits L‑type calcium channels in vascular smooth muscle, causing arterial dilation; and hydrochlorothiazide acts on the distal convoluted tubule to increase sodium and water excretion, lowering plasma volume. Together they produce a complementary reduction in systemic vascular resistance and blood volume, resulting in sustained blood‑pressure control.

Olmesartán/Amlodipino/Hidroclorotiazida may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Flushing: transient warmth and redness.
• Fatigue: feeling of tiredness.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips or airway requiring emergency care.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Electrolyte disturbances: significant potassium or sodium imbalance.
• Renal impairment: sudden decrease in kidney function.

Before initiating therapy, several safety considerations should be evaluated.

• Blood pressure monitoring: check baseline and periodic readings to assess efficacy.
• Renal function assessment: evaluate serum creatinine and eGFR before and during treatment.
• Electrolyte surveillance: monitor potassium and sodium levels, especially with the diuretic component.
• Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited.
• Concomitant medications: review for potential interactions that may affect blood pressure or renal function.
• Store at room temperature: keep tablets in the original pack, protect from moisture and light.

Olmesartán/Amlodipino/Hidroclorotiazida can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Aliskiren: combined use with olmesartan may increase risk of renal impairment and hypotension.
• Potassium‑sparing diuretics or supplements: may cause hyperkalaemia.
• Lithium: increased lithium levels and toxicity.
• NSAIDs: can reduce antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: additive effect on potassium and renal function; monitor labs.
• Beta‑blockers: may enhance blood‑pressure lowering; watch for bradycardia.
• CYP3A4 inhibitors (e.g., erythromycin): may increase amlodipine concentrations.